Chief Executive's blog: The power of collaboration and diversity

Rare diseases by definition are infrequent but they are frequently devastating for patients and their families and can affect people from birth to old age. The Pfizer Rare Disease Consortium inaugural symposium which I was able to attend in part last week was a good opportunity to reconnect with some of my previous colleagues in pharmaceutical R&D as well as academia.

» more